

CHAPTER ONE: INTRODUCTION .....	1
STUDY GOALS AND OBJECTIVES .....	1
REASONS FOR DOING THIS STUDY .....	1
SCOPE OF REPORT .....	1
INTENDED AUDIENCE.....	1
METHODOLOGY .....	2
INFORMATION SOURCES .....	2
ANALYST CREDENTIALS .....	2
RELATED REPORTS .....	2
BCC ONLINE SERVICES.....	3
DISCLAIMER .....	3
CHAPTER TWO: SUMMARY.....	4
SUMMARY TABLE WORLDWIDE POTENTIAL MARKET FOR MEMORY/COGNITION THERAPEUTICS, BY DISEASE AREA, THROUGH 2014 (\$ MILLIONS).....	4
SUMMARY FIGURE WORLDWIDE MEMORY/COGNITION THERAPEUTICS MARKET, BY DISEASE AREA, 2008 (%).....	5
DISEASE STATES .....	6
DISEASE STATES (CONTINUED) .....	7
TREATMENTS IN DEVELOPMENT.....	8
THE FUTURE.....	9
CHAPTER THREE: OVERVIEW .....	10
DEFINITION AND MARKET STRUCTURE.....	10
WHAT IS COGNITION? .....	10
COMPONENT SYSTEMS .....	11
Working Memory .....	11
Knowledge Base (Long-term Memory) .....	11
Executive System.....	12
Response System .....	12
COMPONENT PROCESSES.....	13
Attention .....	13
Perception .....	13
Memory and Learning .....	13
Organization .....	13
Reasoning and Problem Solving .....	14
COGNITION VERSUS MEMORY .....	14
HOW ARE COGNITION AND MEMORY MEASURED? .....	15
TABLE 1 DIAGNOSTIC TESTS.....	15
TABLE 1 (CONTINUED).....	16
THE CHALLENGE .....	17
MAIN DISEASE AREAS .....	18
MARKET SIZE AND KEY PLAYERS.....	18

<i>TABLE 2 TOP COMPANIES WORKING IN MEMORY AND COGNITION AND ASSOCIATED WORLDWIDE MARKET SHARE (%)</i> .....	19
HISTORY.....	19
FUTURE DEVELOPMENT.....	19
CHAPTER FOUR: APPLICATIONS .....	20
PRIMARY.....	20
<i>TABLE 3 DEMENTIA RATE BY UNDERLYING DISEASE STATE (%)</i> .....	20
<i>FIGURE 1 DEMENTIA CASES BY UNDERLYING DISEASE STATE (%)</i> .....	21
SECONDARY.....	22
MEDICATION-RELATED.....	22
SUBSTANCE ABUSE.....	23
CREUTZFELDT JAKOB DISEASE.....	23
Creutzfeldt Jakob Disease (Continued).....	24
ADHD.....	25
MULTIPLE SCLEROSIS.....	25
Multiple Sclerosis (Continued).....	26
INFECTIOIN.....	27
METABOLIC DISORDERS.....	27
BRAIN TUMORS.....	28
CABG.....	28
<i>TABLE 4 PERCENT OF PATIENTS WITH DEMENTIA/COGNITIVE DEFICIT (%)</i> .....	28
PRIMARY.....	28
ALZHEIMER'S DISEASE.....	28
<i>TABLE 5 WORLDWIDE DISEASE PREVALENCE: ALZHEIMER'S DISEASE (%)</i> .....	29
<i>TABLE 6 EXISTING TREATMENTS: ALZHEIMER'S DISEASE</i> .....	29
Role of the Cholinergic System.....	29
Role of Beta-Amyloid Protein.....	30
<i>TABLE 7 TREATMENT FORECAST FOR ALZHEIMER'S DISEASE, THROUGH 2014 (\$ MILLIONS)</i> .....	31
<i>FIGURE 2 TREATMENT FORECAST FOR ALZHEIMER'S DISEASE, 2007-2014 (\$ MILLIONS)</i> .....	31
VASCULAR DEMENTIA.....	32
<i>TABLE 8 WORLDWIDE DISEASE PREVALENCE: VASCULAR DEMENTIA (%)</i> .....	32
<i>TABLE 9 EXISTING TREATMENTS: VASCULAR DEMENTIA</i> .....	32
Cause.....	33
VCIND.....	34
Binswanger's Disease.....	34
Multi-Infarct Dementia.....	34
Treatment.....	35

<i>TABLE 10 TREATMENT FORECAST FOR VASCULAR DEMENTIA, THROUGH 2014 (\$ MILLIONS)</i> .....	35
<i>FIGURE 3 TREATMENT FORECAST FOR VASCULAR DEMENTIA, 2007-2014 (\$ MILLIONS)</i> .....	36
Counseling and Psychotherapy .....	37
Pharmacotherapy.....	37
Outlook .....	38
LEWY BODY DEMENTIA .....	38
<i>TABLE 11 WORLDWIDE DISEASE PREVALENCE: LEWY BODY DEMENTIA (%)</i> .....	39
Treatment .....	39
<i>TABLE 12 EXISTING TREATMENTS: LBD</i> .....	40
Outlook.....	40
<i>TABLE 13 TREATMENT FORECAST FOR LBD, THROUGH 2014 (\$ MILLIONS)</i> .....	40
<i>FIGURE 4 TREATMENT FORECAST FOR LBD, 2007-2014 (\$ MILLIONS)</i> .....	41
PARKINSON'S DISEASE.....	41
Parkinson's Disease (Continued) .....	42
Other Parkinsonism Syndromes .....	43
Recognizing Other Causes of Parkinsonism .....	43
Medication-Induced Parkinsonism .....	44
Corticobasal Degeneration (CBD) .....	44
Multiple System Atrophy (MSA).....	44
Multiple System Atrophy (Continued).....	45
Multiple System Atrophy (Continued).....	46
SCHIZOPHRENIA .....	47
Schizophrenia (Continued).....	48
Schizophrenia (Continued).....	49
<i>TABLE 14 WORLDWIDE DISEASE PREVALENCE: SCHIZOPHRENIA (%)</i> .....	50
Treatment .....	50
<i>TABLE 15 EXISTING TREATMENTS: SCHIZOPHRENIA</i> .....	51
<i>TABLE 16 TREATMENT FORECAST FOR COGNITION IN SCHIZOPHRENIA (CIAS), THROUGH 2014 (\$ MILLIONS)</i> .....	51
<i>FIGURE 5 TREATMENT FORECAST FOR COGNITION IN SCHIZOPHRENIA (CIAS), 2007-2014 (\$ MILLIONS)</i> .....	52
Treatment (Continued) .....	53
Outlook.....	54
MCI/AAMI .....	54
<i>TABLE 17 WORLDWIDE DISEASE PREVALENCE: MCI/AAMI (%)</i> .....	55
<i>TABLE 18 EXISTING TREATMENTS: MCI/AAMI</i> .....	55
<i>TABLE 19 TREATMENT FORECAST FOR MCI/AAMI, THROUGH 2014 (\$ MILLIONS)</i> .....	55

<i>FIGURE 6 TREATMENT FORECAST FOR MCI/AAMI, 2007-2014 (\$ MILLIONS)</i> .....	56
HUNTINGTON'S DISEASE.....	56
Demographics .....	57
<i>TABLE 20 WORLDWIDE DISEASE PREVALENCE: HUNTINGTON'S DISEASE (%)</i> .....	57
<i>TABLE 21 EXISTING TREATMENTS: HUNTINGTON'S DISEASE</i> .....	57
Demographics (Continued) .....	58
Treatment .....	59
<i>TABLE 22 TREATMENT FORECAST FOR HUNTINGTON'S DISEASE, THROUGH 2014 (\$ MILLIONS)</i> .....	60
<i>FIGURE 7 TREATMENT FORECAST FOR HUNTINGTON'S DISEASE, 2007-2014 (\$ MILLIONS)</i> .....	61
HIV-RELATED MEMORY AND COGNITION EFFECTS .....	61
<i>TABLE 23 WORLDWIDE DISEASE PREVALENCE: HIV-RELATED (%)</i> .....	62
<i>TABLE 24 EXISTING TREATMENTS: HIV-RELATED</i> .....	63
<i>TABLE 25 TREATMENT FORECAST FOR HIV-RELATED, THROUGH 2014 (\$ MILLIONS)</i> .....	63
<i>FIGURE 8 TREATMENT FORECAST FOR HIV-RELATED, 2007-2014 (\$ MILLIONS)</i> .....	64
GENETIC DISEASES.....	64
<i>TABLE 26 WORLDWIDE DISEASE PREVALENCE: GENETIC DISEASES (%)</i> .....	64
<i>TABLE 27 EXISTING TREATMENTS: GENETIC DISEASES</i> .....	65
<i>TABLE 28 TREATMENT FORECAST FOR GENETIC DISEASES: COGNITION ONLY, THROUGH 2014 (\$ MILLION)</i> .....	65
<i>FIGURE 9 TREATMENT FORECAST FOR GENETIC DISEASES, 2007-2014 (\$ MILLIONS)</i> .....	66
Pick's Disease.....	66
Krabbe Disease .....	67
Krabbe Disease (Continued).....	68
CHAPTER FIVE: MECHANISMS OF ACTION .....	69
MECHANISMS OF ACTION .....	69
<i>TABLE 29 MARKETED TREATMENTS: ALL DISEASES</i> .....	70
COMMON MECHANISMS .....	71
CHOLINESTERASE INHIBITORS .....	71
<i>TABLE 30 CHOLINESTERASE INHIBITORS</i> .....	71
NMDA Antagonists .....	71
<i>TABLE 31 NMDA ANTAGONISTS</i> .....	72
Nicotinics .....	72
<i>TABLE 32 NICOTINIC ACETYLCHOLINE ANTAGONISTS</i> .....	73
Calcineurins.....	73
<i>TABLE 33 CALCINEURINS</i> .....	73
GABA Modulators.....	74

<i>TABLE 34 ANTI-EPILEPTIC/GABA MODULATORS</i> .....	74
Hormones .....	75
<i>TABLE 35 HORMONES</i> .....	75
OTHER MECHANISMS .....	75
COGNITION ENHANCERS IN DEVELOPMENT .....	76
DRUGS FOR DISEASE MODIFICATION .....	76
Secretase Inhibitors .....	76
Metal Chelation .....	76
Vaccines .....	76
Statins .....	76
Neurotransmitter Targets .....	77
NSAIDS .....	77
Antioxidants .....	77
Hormones .....	78
Other Agents .....	78
<i>TABLE 36 OVERVIEW OF MEMORY/COGNITION TREATMENTS</i> .....	78
<i>TABLE 36 (CONTINUED)</i> .....	79
<i>TABLE 37 DEVELOPMENT PIPELINE OF MEMORY/COGNITION</i>	
<i>DRUGS, BY DEVELOPMENT STATUS</i> .....	79
<i>TABLE 37 (CONTINUED)</i> .....	80
<i>TABLE 37 (CONTINUED)</i> .....	81
<i>TABLE 37 (CONTINUED)</i> .....	82
<i>TABLE 37 (CONTINUED)</i> .....	83
<i>TABLE 37 (CONTINUED)</i> .....	84
<i>TABLE 37 (CONTINUED)</i> .....	85
<i>FIGURE 10 DEVELOPMENT PIPELINE OF MEMORY/COGNITION</i>	
<i>DRUGS: NUMBER OF PROGRAMS AT EACH CLINICAL STAGE</i> .....	85
Glutamate .....	86
Calcium Channels .....	86
Maxi-K Channels .....	86
CREB and Phosphodiesterase .....	87
Acetylcholine .....	87
Dopamine .....	87
Serotonin .....	88
GABA .....	88
The Cannabinoid System .....	88
Histamine .....	89
Neurohormones and Neuropeptides .....	89
Other Molecular Targets .....	89
Genome and Stem Cells .....	90
FUTURE COGNITION ENHANCERS .....	91
Changes in Society .....	91
Increasing Knowledge .....	91
Scientific Limitations .....	92

Implications .....	93
Potential Benefits and Harms.....	93
Health Economics .....	94
Regulation, Ethics, and Society .....	94
<i>TABLE 38 OTC TREATMENTS/NATURAL PRODUCTS.....</i>	<i>95</i>
OTC TREATMENTS .....	96
Ginkgo .....	97
GENE THERAPY.....	98
STIMULANTS.....	98
Stimulants (Continued).....	99
CHAPTER SIX: WORLDWIDE INDUSTRY STRUCTURE.....	100
GROWTH DRIVERS.....	100
<i>TABLE 39 TOP-SELLING MEMORY AND COGNITION DRUGS (\$</i>	
<i>MILLIONS).....</i>	<i>100</i>
AGING POPULATION .....	100
Aging Population (Continued).....	101
OFF-LABEL USE.....	102
UNDERSTANDING OF MECHANISMS .....	103
Transcranial Magnetic Stimulation.....	104
Genetic Modifications .....	105
GROWTH OBSTACLES .....	105
UNDERSTANDING OF MECHANISMS .....	106
<i>TABLE 40 CLINICAL SUCCESS RATES BY THERAPEUTIC AREA (%)....</i>	<i>106</i>
<i>FIGURE 11 CLINICAL SUCCESS RATES BY THERAPEUTIC AREA</i>	
<i>(%).....</i>	<i>106</i>
CO-MORBID DISEASE STATES.....	107
ACCEPTANCE OF MEMORY AND COGNITION AS	
TREATABLE CONDITIONS .....	107
TREATMENT OF CHILDREN.....	107
Treatment of Children (Continued).....	108
KEY COMPETITIVE FACTORS .....	109
PRODUCT LAUNCH.....	109
LIFE CYCLE MANAGEMENT .....	109
INDUSTRY LEADERS.....	110
MERCK.....	110
<i>TABLE 41 MERCK MEMORY AND COGNITION PIPELINE.....</i>	<i>110</i>
ROCHE .....	110
<i>TABLE 42 ROCHE MEMORY AND COGNITION PIPELINE.....</i>	<i>110</i>
PFIZER.....	111
<i>TABLE 43 PFIZER MEMORY AND COGNITION PIPELINE.....</i>	<i>111</i>
SHIRE.....	111
<i>TABLE 44 SHIRE MEMORY AND COGNITION PIPELINE.....</i>	<i>111</i>
CEPHALON .....	112
<i>TABLE 45 CEPHALON MEMORY AND COGNITION PIPELINE.....</i>	<i>112</i>

PAYORS .....	112
PAYORS (CONTINUED).....	113
INTERNATIONAL ASPECTS .....	114
<i>TABLE 46 PER CAPITA GOVERNMENT EXPENDITURE ON HEALTHCARE BY COUNTRY, THROUGH 2006 (\$ MILLIONS).....</i>	<i>115</i>
BIOTECHNOLOGY CLUSTERS.....	116
LEGISLATION AND REGULATORY ENVIRONMENT .....	116
VALIDATED TARGETS.....	116
LACK OF BIOMARKERS .....	116
TRANSLATIONAL MEDICINE.....	117
REIMBURSEMENT .....	118
SCHEDULING STATUS.....	119
MEMORY AND COGNITION AS A STAND-ALONE INDICATION .....	119
RELATED DEALS AND PARTNERSHIPS .....	119
RELATED DEALS AND PARTNERSHIPS (CONTINUED) .....	120
<i>TABLE 47 RELATED DEALS AND PARTNERSHIPS, 2002-2008.....</i>	<i>121</i>
<i>TABLE 47 (CONTINUED).....</i>	<i>122</i>
<i>TABLE 47 (CONTINUED).....</i>	<i>123</i>
CHAPTER SEVEN: PATENT ANALYSIS .....	124
INTRODUCTION .....	124
TRENDS BY COUNTRY .....	124
<i>TABLE 48 PATENT ANALYSIS MAJOR U.S. PATENT HOLDERS IN MEMORY/COGNITION DISORDERS.....</i>	<i>124</i>
<i>FIGURE 12 MAJOR PATENT HOLDERS BY ASSIGNEE (%).....</i>	<i>125</i>
TRENDS BY ASSIGNEE .....	125
TRENDS BY TECHNOLOGY .....	126
<i>TABLE 49 U.S. PATENT APPLICATIONS.....</i>	<i>127</i>
<i>TABLE 49 (CONTINUED).....</i>	<i>128</i>
<i>TABLE 49 (CONTINUED).....</i>	<i>129</i>
<i>TABLE 49 (CONTINUED).....</i>	<i>130</i>
<i>TABLE 49 (CONTINUED).....</i>	<i>131</i>
<i>TABLE 49 (CONTINUED).....</i>	<i>132</i>
<i>TABLE 49 (CONTINUED).....</i>	<i>133</i>
<i>TABLE 49 (CONTINUED).....</i>	<i>134</i>
<i>TABLE 50 U.S. PATENTS GRANTED.....</i>	<i>135</i>
<i>TABLE 50 (CONTINUED).....</i>	<i>136</i>
<i>TABLE 50 (CONTINUED).....</i>	<i>137</i>
<i>TABLE 50 (CONTINUED).....</i>	<i>138</i>
<i>TABLE 50 (CONTINUED).....</i>	<i>139</i>
<i>TABLE 50 (CONTINUED).....</i>	<i>140</i>
<i>TABLE 50 (CONTINUED).....</i>	<i>141</i>
<i>TABLE 50 (CONTINUED).....</i>	<i>142</i>
CHAPTER EIGHT: OUTLOOK: TRENDS AND CHALLENGES .....	143

GENERAL TRENDS.....	143
GENERAL TRENDS (CONTINUED) .....	144
ETHICAL IMPLICATIONS .....	145
ETHICAL IMPLICATIONS (CONTINUED) .....	146
CHAPTER NINE: COMPANY PROFILES .....	147
ACADIA PHARMACEUTICALS.....	147
ACCERA, INC. ....	147
ACUMEN PHARMACEUTICALS .....	147
ALLON THERAPEUTICS (FKA NEURODISCOVERY).....	147
ALZHYME PTY.....	148
AMARIN PHARMACEUTICALS.....	148
ASTRAZENECA.....	148
BRAINCELLS, INC. ....	149
COGNITION PHARMACEUTICALS .....	149
COLUCID PHARMACEUTICALS.....	149
COMENTIS .....	149
CORTEX PHARMACEUTICALS.....	150
ENVIVO PHARMACEUTICALS .....	150
GALENEA .....	150
GLAXOSMITH KLINE.....	151
HELICON THERAPEUTICS .....	151
INTELLECT NEUROSCIENCES.....	151
INTRA-CELLULAR THERAPIES .....	151
IPSEN.....	152
LEXICON PHARMACEUTICALS .....	152
MEDIVATION.....	152
MEMORY PHARMACEUTICALS .....	152
MERCK .....	153
MERCKSERONO.....	153
MITHRIDION .....	153
NEUREN PHARMACEUTICALS.....	153
NEUROSEARCH .....	153
NEURO-HITECH .....	154
NEWRON PHARMACEUTICALS .....	154
NOVARTIS .....	154
PFIZER.....	154
PRANA BIOTECHNOLOGY .....	155
PSYCHOGENICS .....	155
SANOFI-AVENTIS .....	155
SATORI PHARMACEUTICALS .....	155
SCIELE PHARMA .....	155
SEASIDE THERAPEUTICS .....	156
SHIRE.....	156
TAKEDA.....	156



TARGACEPT.....	156
TAURX THERAPEUTICS.....	156
TEVA PHARMACEUTICALS.....	157
VOYAGER PHARMACEUTICAL / DURAMED.....	157
WYETH.....	157
APPENDIX:.....	158
COMPANY LISTING.....	158
ACADIA PHARMACEUTICALS, INC.....	158
ACCERA, INC.....	158
ACUMEN PHARMACEUTICALS, INC.....	158
ALLON THERAPEUTICS, INC.....	159
ALZHYME, LTD.....	159
AMARIN CORP PLC.....	159
AMARIN PHARMA INC.....	159
ASTRAZENECA.....	160
BRAINCELLS, INC.....	160
COGNITION PHARMACEUTICALS LLC.....	160
COGNITIVE PHARMACEUTICALS LTD.....	160
COLUCID PHARMACEUTICALS.....	160
COMENTIS (FKA ATHENAGEN).....	160
CORTEX PHARMACEUTICALS, INC. 15231 BARRANCA PARKWAY.....	161
ENVIVO PHARMACEUTICALS.....	161
GALENEA CORP.....	161
GLAXOSMITHKLINE.....	161
HELICON THERAPEUTICS, INC.....	161
INTELLECT NEUROSCIENCES, INC.....	162
INTRA-CELLULAR THERAPIES.....	162
IPSEN.....	162
LEXICON PHARMACEUTICALS.....	162
MEDIVATION, INC.....	163
MEMORY PHARMACEUTICALS.....	163
MERCK & CO., INC.....	163
MERCKSERONO.....	163
MITHRIDION.....	163
NEUREN PHARMACEUTICALS, LTD.....	164
NEUROSEARCH A/S.....	164
NEURO-HITECH, INC.....	164
NEWRON.....	164
NOVARTIS.....	165
PFIZER.....	165
PRANA.....	165
PSYCHOGENICS, INC.....	165
SANOFI-AVENTIS.....	165

SATORI PHARMACEUTICALS .....	165
SCIELE PHARMA .....	166
SEASIDE THERAPEUTICS.....	166
SHIRE.....	166
TAKEDA .....	166
TARGACEPT, INC. ....	167
TAURX THERAPEUTICS LTD.....	167
TEVA PHARMACEUTICALS .....	167
VOYAGER PHARMACEUTICALS .....	167
WYETH PHARMACEUTICALS.....	167
Wyeth Pharmaceuticals (Continued).....	168

